Active Filter(s):
Details:
Under the agreement, HK inno.N will receive the exclusive rights to develop and commercialise XW003 (ecnoglutide), a novel GLP-1 analog, in the Republic of Korea. Sciwind Biosciences retains the right to develop and commercialise ecnoglutide in all other global markets.
Lead Product(s): Ecnoglutide
Therapeutic Area: Endocrinology Product Name: XW003
Highest Development Status: Phase III Product Type: Peptide
Recipient: Sciwind Biosciences
Deal Size: $56.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 07, 2024
Details:
As part of this agreement, the companies may open up a discussion on further developments, including clinical development and commercialization, if they succeed in discovering CAR-NK cell product candidates and producing non-clinical samples.
Lead Product(s): Allogeneic CAR-NK Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Recipient: Gicell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 29, 2022
Details:
With the MOU, the two companies plan to collaborate - to discover and develop new drug candidates using exosomes, known as the next game-changer in the drug delivery system.
Lead Product(s): Exosome-loaded Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Recipient: ILIAS Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 27, 2022
Details:
Under this partnership, HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan (CJ-12420), while Dr. Reddy’s will be responsible for local clinical development, registration, marketing and sales in the licensed territories
Lead Product(s): Tegoprazan
Therapeutic Area: Gastroenterology Product Name: CJ-12420
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\\\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 11, 2022
Details:
In the study, cohorts with 50 and 100 milligrams of K-CAB tablets showed superior therapeutic effect and safety in treating gastric ulcers than the group administered with 30 milligrams of Lansoprazole.
Lead Product(s): Tegoprazan
Therapeutic Area: Gastroenterology Product Name: K-CAB
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020